Dacomitinib: an investigational drug for the treatment of glioblastoma

References

• Stupp R, Mason WP, van Den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987–996.
   PubMed Web of Science ®Google Scholar
• Dixit S, Hingorani M, Achawal S, et al. The sequential use of carmustine wafers (Gliadel(R)) and post-operative radiotherapy with concomitant temozolomide followed by adjuvant temozolomide: a clinical review. Br J Neurosurg. 2011;25:459–469.
   PubMed Web of Science ®Google Scholar
• Stupp R, Taillibert S, Kanner A, et al. Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: A randomized clinical trial. JAMA. 2017;318:2306–2316.
   PubMed Web of Science ®Google Scholar
• Brennan CW, Verhaak RG, McKenna A, et al. The somatic genomic landscape of glioblastoma. Cell. 2013;155:462–477.
   PubMed Web of Science ®Google Scholar
• Zahonero C, Aguilera P, Ramírez-Castillejo C, et al. Preclinical test of dacomitinib, an irreversible EGFR inhibitor, confirms its effectiveness for glioblastoma. Mol Cancer Ther. 2015;14(7):1548–1558.
   PubMed Web of Science ®Google Scholar
• Zhu Y, Shah K. Multiple lesions in receptor tyrosine kinase pathway determine glioblastoma response to pan-ERBB inhibitor PF-00299804 and PI3K/mTOR dual inhibitor PF-05212384. Cancer Biol Ther. 2014;15(6):815–822.
   PubMed Web of Science ®Google Scholar
• Sepulveda-Sanchez JM, Vaz MA, Balaña C, et al. Phase II trial of dacomitinib, a pan-human EGFR tyrosin kinase inhibitor, in recurrent glioblastoma patients with EGFR amplification. Neuro-Oncology. 2017;19(11):1522–1531.
   PubMed Web of Science ®Google Scholar
• Gonzales AJ, Hook KE, Althaus IW, et al. Antitumor activity and pharmacokinetic properties of PF-00299804, a second-generation irreversible pan-erbB receptor Tyrosine kinase inhibitor. Mol Cancer Ther. 2008;7:1880–1889.
   PubMed Web of Science ®Google Scholar
• Wu YL, Cheng Y, Zhou X, et al. Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial. Lancet Oncol. 2017;18(11):1454–1466.
   PubMed Web of Science ®Google Scholar
• Mellinghoff IK, Wang MY, Vivanco I, et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med. 2005;353(19):2012–2024.
   PubMed Web of Science ®Google Scholar
• Zahonero C, Sanchez-Gomez P. EGFR-dependent mechanisms in glioblastoma: towards a better therapeutic strategy. Cell Mol Life Sci. 2014;71(18):3465–3488.
   PubMed Web of Science ®Google Scholar
• Chakravarti A, Zhai G, Suzuki Y, et al. The prognostic significance of phosphatidylinositol 3-kinase pathway activation in human gliomas. J Clin Oncol. 2004;22:1926–1933.
   PubMed Web of Science ®Google Scholar
• Furnari FB, Fenton T, Bachoo RM, et al. Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev. 2017;21(21):2683–2710.
   Google Scholar
• Ohgaki H, Kleihues P. The definition of primary and secondary glioblastoma. Clin Cancer Res. 2013;19(4):764–772.
   PubMed Web of Science ®Google Scholar
• Zhu H, Acquaviva J, Ramachandran P, et al. Oncogenic EGFR signaling cooperates with loss of tumor suppressor gene functions in gliomagenesis. Proc Natl Acad Sci USA. 2009;106(8):2712–2716.
   PubMed Web of Science ®Google Scholar
• Li L, Dutra A, Pak E, et al. EGFRvIII expression and PTEN loss synergistically induce chromosomal instability and glial tumors. Neuro Oncol. 2009;11(1):9–21.
   PubMed Web of Science ®Google Scholar
• Read RD, Cavenee WK, Furnari FB, et al. A drosophila model for EGFR-Ras and PI3K-dependent human glioma. PLoS Genet. 2009;5(2):e1000374.
   PubMed Web of Science ®Google Scholar
• Huang PH, Xu AM. White FM: oncogenic EGFR signaling networks in glioma. Sci Signal. 2009;2:re6.
   PubMed Web of Science ®Google Scholar
• Greenall SA, Donoghue JF, Gottardo NG, et al. Glioma-specific Domain IV EGFR cysteine mutations promote ligand-induced covalent receptor dimerization and display enhanced sensitivity to dacomitinib in vivo. Oncogene. 2015;34(13):1658–1666.
   PubMed Web of Science ®Google Scholar
• Endersby R, Whitehouse J, Hii H, et al. A preclinical assessment of the Pan-ERBB inhibitor dacomitinib in pediatric and adult brain tumors. Neoplasia. 2018;20:1–11.
   PubMed Web of Science ®Google Scholar
• Hegi ME, Diserens AC, Bady P, et al. Pathway analysis of glioblastoma tissue after preoperative treatment with the EGFR tyrosine kinase inhibitor gefitinib–a phase II trial. Mol Cancer Ther. 2011;10(6):1102–1112.
   PubMed Web of Science ®Google Scholar
• Yoshida Y, Ozawa T, Yao TW, et al. NT113, a pan-ERBB inhibitor with high brain penetrance, inhibits the growth of glioblastoma xenografts with EGFR amplification.
   Google Scholar
• Haas-Kogan DA, Prados MD, Tihan T, et al. Epidermal growth factor receptor, protein kinase B/ Akt,and glioma response to erlotinib. J Natl Cancer Inst. 2005;97(12):880–887.
   PubMed Web of Science ®Google Scholar
• Learn CA, Hartzell TL, Wikstrand CJ, et al. Resistance to tyrosine kinase inhibition by mutant epidermal growth factor receptor variant III contributes to the neoplastic phenotype of glioblastoma multiforme. Clin Cancer Res. 2004;10(9):3216–3224.
   PubMed Web of Science ®Google Scholar
• Pedersen MW, Pedersen N, Ottesen LH, et al. Differential response to gefitinib of cells expressing normal EGFR and the mutant EGFRvIII. Br J Cancer. 2005;93(8):915–923.
   PubMed Web of Science ®Google Scholar
• Schulte A, Liffers K, Kathagen A, et al. Erlotinib resistance in EGFR-amplified glioblastoma cells is associated with upregulation of EGFRvIII and PI3Kp110δ. Neuro Oncol. 2013;15(10):1289–1301.
   PubMed Web of Science ®Google Scholar
• van Den Bent MJ, Brandes AA, Rampling R, et al. Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034. J Clin Oncol. 2009;27(8):1268–1274.
   PubMed Web of Science ®Google Scholar
• Peereboom DM, Shepard DR, Ahluwalia MS, et al. Pahse II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiforme. J Neurooncol. 2010;98(1):93–99.
   PubMed Web of Science ®Google Scholar
• Wen PY, Chang SM, Lamborn KR, et al. Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American brain tumor consortium trial 04-02. Neuro Oncol. 2014;16(4):567–578.
   PubMed Web of Science ®Google Scholar
• Uhm JH, Ballman KV, Wu W, et al. Phase II evaluation of gefitinib in patients with newly diagnosed Grade 4 astrocytoma: mayo/North central cancer treatment group study N0074. Int J Radiat Oncol Biol Phys. 2011;80(2):347–353.
   PubMed Web of Science ®Google Scholar
• Readon DA, Groves MD, Wen PY, et al. A pase I/II trial of pazopanib in combination with lapatinib in adult patients with relapsed malignant glioma. Clin Cancer Res. 2013;19(4):900–908.
   PubMed Web of Science ®Google Scholar
• Neyns B, Sadones J, Joosens E, et al. Stratified phase II trial of cetuximab in patients with recurrent high-grade glioma. Ann Oncology. 2009;20(9):1596–1603.
   PubMed Web of Science ®Google Scholar
• Bode U, Massimino M, Bach F, et al. Nimotuzumab treatment of amlignant gliomas. Exp Opin Biol Ther. 2012;12:649–659.
   PubMed Web of Science ®Google Scholar
• Reardon DA, Nabors LB, Mason WP, et al. Phase I/randomized phase II study of afatinib, an irreversible ErbB family blocker, with or without protracted temozolomide in adults with recurrent glioblastoma. Neuro Oncol. 2015;17(3):430–439.
   PubMed Web of Science ®Google Scholar
• Galanis E, Wu W, Cloughesy T, et al. Phase 2 trial design in neuro-oncology revisited: a report from the RANO group. Lancet Oncol. 2012;13:e196–204.
   PubMed Web of Science ®Google Scholar
• Wen PY, Macdonald DR, Reardon DA, et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol. 2010;28:1963–1972.
   PubMed Web of Science ®Google Scholar
• Bello CL, LaBadie RR, Ni G, et al. The effect of dacomitinib (PF-00299804) on CYP2D6 activity in healthy volunteers who are extensive or intermediate metabolizers. Cancer Chemother Pharmacol. 2012;69:991–997.
   PubMed Web of Science ®Google Scholar
• Lassman AB, Rossi MR, Raizer JJ, et al. Molecular study of malignant gliomas treated with epidermal growth factor receptor inhibitors: tissue analysis from North American brain tumor consortium trials 01-03 and 00-01. Clin Cancer Res. 2005;11:7841–7850.
   PubMed Web of Science ®Google Scholar
• Padfield E, Ellis HP, Kurian KM. Current therapeutic advances targeting EGFR and EGFRvIII in glioblastoma. Front Oncol. 2015;5:5–10.
   PubMed Web of Science ®Google Scholar
• Felsberg J, Hentschel B, Kaulich K, et al. Epidermal growth factor receptor variant III (EGFRvIII) positivity in EGFR-amplified glioblastomas: prognostic role and comparison between primary and recurrent tumors. Clin Cancer Res. 2017;23:6846–6855.
   PubMed Web of Science ®Google Scholar